T1	Participants 499 630	patients were randomized to receive either placebo or nifedipine SR-20 mg (study I only), 50 mg, 100 mg, or 150 mg (study II only).
T2	Participants 381 453	388 patients with mild to moderate uncomplicated essential hypertension.
